Drug Profile
Exenatide biobetter - Biolingus
Alternative Names: BL OPUS II; Exenatide oral - Biolingus; Exenatide sublingual - Biolingus; Project A1 (OPUS) - BiolingusLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Vitapharm Technology Development
- Developer Biolingus; Vitapharm Technology Development
- Class Antihyperglycaemics; Biobetters; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Switzerland (Sublingual, Tablet)
- 15 Sep 2020 Preclinical trials in Obesity in Switzerland (Sublingual) (Biolingus pipeline, September 2020)
- 18 Sep 2017 Exanatide biobetter - Biolingus is available for licensing as of 18 Sep 2017. http://www.biolingus.ch/index.html#partners